Status:
UNKNOWN
The National Register of Antipsychotic Medication in Pregnancy (NRAMP)
Lead Sponsor:
The Alfred
Collaborating Sponsors:
Janssen-Cilag Ltd.
AstraZeneca
Conditions:
Pregnancy
Mental Disorders
Eligibility:
FEMALE
18-50 years
Brief Summary
The National Register of Antipsychotic Medication in Pregnancy (NRAMP)is an observational, nationwide study involving women of child-bearing age who take antipsychotic medication during pregnancy. It ...
Detailed Description
The desire to reproduce is both a powerful urge and a basic human right for women regardless of mental health status. Deinstitutionalised treatment for mental illness, better pharmacotherapies, and ge...
Eligibility Criteria
Inclusion
- Women who take antipsychotic medication during pregnancy
- Women who are pregnant or have had a baby in the last 12 months
- Women who are living in Australia
- Women who are able to provide informed consent
Exclusion
- Women who do not take antipsychotic medication during pregnancy
- Women who are not pregnant, or have not had a baby in the last 12 months
- Women who are unable to provide informed consent
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00686946
Start Date
January 1 2005
End Date
December 1 2025
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Monash Alfred Pyschiatry Research Centre, Alfred Hospital
Melbourne, Victoria, Australia, 3004